Medication Characteristics Research Articles

Apixaban, a Novel Oral Anticoagulant, Use to Resolute Arterial Patency in Radial Artery Occlusion Due to Cardiac Catheterization; A Pilot Randomized Clinical Trial.

In recent years, transradial cardiac catheterization has become the preferred method. However, it can result in a significant complication known as radial artery occlusion (RAO). The medical management of RAO remains controversial, especially with the emergence of novel oral anticoagulants. Nevertheless, there is limited data on the use of these agents for treating RAO, which is the focus of this study using apixaban. This pilot double-blinded randomized clinical trial involved 30 patients who developed RAO following transradial coronary angiography. The patients were randomly assigned to receive either apixaban (2.5 mg twice daily) or a conservative approach for 30 days. Doppler ultrasonography was performed at baseline and at the end of the intervention to assess radial artery diameter and the resolution of arterial patency. Demographic, medical, medication, and clinical characteristics were collected. The mean age of the studied population was 59.43±12.14 years, and the majority were males (60%). Radial artery resolution was observed in 21 (70%) patients, independent of medication use. There was no significant association between resolution and age (P-value=0.62), gender (P-value=0.74), body mass index (P-value=0.23), smoking (P-value=0.64), diabetes (P-value=0.999), hypertension (P-value=0.74), statins (P-value=0.999), antiplatelet therapy (P-value=0.999), length of angiography (P-value=0.216), or follow-up arterial diameter (P-value=0.304). Recanalization occurred in 13 (86.7%) cases in the apixaban treatment group, compared to 8 (53.3%) individuals in the control group, indicating a significant difference (P-value=0.046). The study findings suggest no demographic, medical, medication, or clinical factors were associated with arterial recanalization. However, a one-month treatment with apixaban at a dose of 2.5 mg twice daily appeared to be effective.

Master Cao's Experience in Treating Lung Cancer

Objective: To explore the drug use law of Director Cao Liping in the treatment of lung cancer. Methods: 150 cases of medical records were collected and the characteristics of medication were analyzed with the help of "Traditional Chinese Medicine Inheritance Computing Platform (V3.0)".Results: The four Qi are mainly cold, warm and calm; The five flavors are mainly bitter, spicy and sweet; Meridians are mainly lung, spleen and stomach meridians; Its efficacy is mainly in resolving phlegm, relieving cough and asthma, tonifying deficiency and clearing heat. There are 26 drugs with frequency of more than 30 times, 41 groups of high-frequency drug combinations, and 4 groups of core prescriptions. Conclusion: The key of lung cancer is to strengthen the spleen and clear the lung, strengthen the spleen and clear the lung, supplement the deficiency and strengthen the right, and detoxify and remove the turbidity. The prescription can be used flexibly.

Veterans affairs serious mental illness patients: Differences in high-intensity service use by personality disorder status.

Individuals with serious mental illnesses (SMI) or personality disorders (PD) have complex treatment needs and are at risk of adverse outcomes. Yet, little is known about the impact of comorbid SMI and PD on risk factors. This study used the Veterans Health Administration (VHA)'s corporate data warehouse (CDW) to assess the differences between those with and without a comorbid PD, as well as the prevalence and impact of PD diagnoses on high-intensity/emergency service utilization in VHA patients with a SMI diagnosis (schizophrenia spectrum disorders and bipolar spectrum disorders). In fiscal year 2018, 163,904 VHA patients had encounters that listed SMI diagnoses, including 9,216 patients who had encounters that listed PD diagnoses. Bivariate analyses and logistic regression were used to compare group characteristics and determine whether a PD diagnosis was associated with utilization of high-intensity care services. The SMI with no PD and SMI with comorbid PD (SMI-PD) groups differed in terms of demographic, medication, clinical, and service utilization characteristics, including that the SMI-PD group was 5.25 times more likely to have documented suicide risk and 4.73 times more likely to have documented behavioral risk. After controlling for multiple patient characteristics, patients in the SMI-PD group were 1.35 times more likely to have some emergency department (ED) utilization and 1.94 times more likely to have some inpatient mental health use. Having a diagnosed comorbid PD was associated with increased prevalence of medical and psychiatric problems. Findings suggest that patients with comorbid PDs have particularly high-treatment needs and may benefit from assessment of, and adapted treatments for, PDs. (PsycInfo Database Record (c) 2022 APA, all rights reserved).

A Multisite Qualitative Analysis of Perceived Roles in Medication Safety: Older Adults' Perspectives.

Older adults and caregivers play an essential role in medication safety; however, self-perception of their and health professionals' roles in medication safety is not well-understood. The objective of our study was to identify the roles of patients, providers, and pharmacists in medication safety from the perspective of older adults. Semi-structured qualitative interviews were held with 28 community-dwelling older adults over 65 years who took five or more prescription medications daily. Results suggest that older adults' self-perceptions of their role in medication safety varied widely. Older adults perceived that self-learning about their medications and securing them are critical to avoiding medication-related harm. Primary care providers were perceived as coordinators between older adults and specialists. Older adults expected pharmacists to inform them of any changes in the characteristics of medications to ensure medications were taken correctly. Our findings provide an in-depth analysis of older adults' perceptions and expectations of their providers' specific roles in medication safety. Educating providers and pharmacists about the role expectations of this population with complex needs can ultimately improve medication safety.

Building Demand for Deprescribing Expertise: Pharmacists as Deprescribing Care Coordinators.

A number of barriers to deprescribing exist, with knowledge, skills, and self-efficacy often highlighted by prescribers within an interrupted, siloed nature of the existing health care system. Thus, deprescribing is not likely to occur without a change in the system. Pharmacists are extremely well positioned to positively impact the deprescribing process, and particularly senior care pharmacists given familiarity with population-specific pharmacodynamic and pharmacokinetic characteristics of medications. Similarly, our health care partners have endorsed pharmacists to not only collaborate but to drive the deprescribing trials. Therefore, no other profession is better positioned to advocate for the value of deprescribing as a core component of the pharmaceutical care process.

Analysis of the Prescription Regularities of Proprietary Chinese Medicines for Insomnia Based on Data mining

Objective: To analyze the medication characteristics and regularities of proprietary Chinese medicines for the treatment of insomnia, and to provide new ideas for the clinical treatment of this disease and the research and development of proprietary Chinese medicines. Methods: The prescriptions of proprietary Chinese medicines for the treatment of insomnia were collected from“yaoZH” database, and then Excel 2016, and SPSS Modeler18.0 was employed for frequency statistics, correlation analysis and Apriori association rule. Analysis graphs were drawn using Cytoscape to summarize the patterns of medication use Results: A total of 152 prescriptions were finally screened, involving 336 Chinese herbal medicines, with a cumulative frequency of 1433. The top 5 drugs with the highest cumulative frequency were Danggui (3.07%), Fuling (2.86%), Wuweizi (2.86%), Shudihuang (2.58%) and Huangqi (2.37%). The first place of each order of the drug-drug association rule was Danggui→ Zhiyuanzhi, Chaosuanzaoren+ Danggui→ Fuling; the first place of each order of the drug-symptom association rule was Fuling → Insomnia, Fuling + Danggui → Insomnia. In addition, 152 Chinese patent medicines could treat a total of 66 TCM syndromes, and the top 5 syndromes with the highest treatment frequency were Qi and Blood Deficiency Syndrome (16.5%), Liver and Kidney Deficiency Syndrome (10.9%), Heart and Spleen Deficiency Syndrome (5.21%), Qi and Yin Deficiency Syndrome (4.73%), and Liver Yang Hyperactivity Syndrome (4.26%). Conclusion: The treatment of insomnia with proprietary Chinese medicines is focused on nourishing deficiency, and is particularly good at treating insomnia caused by deficiency of Qi and Blood, deficiency of Liver and Kidney or deficiency of Heart and Spleen, and its main treatment symptoms, apart from insomnia, are most often accompanied by palpitations, fatigue, dizziness and memory loss, which can provide a basis for the clinical treatment of insomnia and the development of proprietary Chinese medicines.

Developmental toxicity window of fetal testicular injury in offspring mice induced by prenatal amoxicillin exposure at different time, doses and courses

Amoxicillin is widely used in the clinical treatment of syphilis, gonorrhea and other infectious diseases during pregnancy, but the effects of prenatal amoxicillin exposure (PAmE) on fetal testicular development have not been reported. Based on the characteristics of clinical medication, Kunming mice were orally gavaged with amoxicillin during pregnancy at different time (mid- or late-pregnancy), doses (75, 150 or 300 mg/kg·d) or courses (single- or multi-course). The results showed that compared with the control group, PAmE resulted in fetal testicular abnormal morphological development, cell proliferation inhibition and apoptosis enhancement, Leydig cell steroid synthase system (SF1, StAR, P450scc, CYP17a1) expression inhibition, and fetal blood testosterone levels decreased. Among them, the late-pregnancy and high-dose amoxicillin groups had severe damage, while the damage in different course groups was basically the same. Meanwhile, PAmE could damage the number and function of germ cells at all time, doses and courses, but had no obvious effect on Sertoli cells. It was further found that PAmE inhibited fetal testis AKT and ERK signaling pathways in late pregnancy and high dose, while the damage in different course groups was basically the same. In summary, this study proposed the developmental toxicity window of fetal testicular injury induced by PAmE in late-pregnancy and high-dose and its related mechanism of AKT and ERK signaling pathway, which provided a theoretical and experimental basis for guiding rational drug use during pregnancy and effectively evaluating the risk of fetal testicular developmental toxicity.

The characteristics of restrictive listings of medications: the position of orphan medical preparations

In the Russian Federation, the regulations on making out restrictive listings of medications were established as separate Government Order in 2014. Since this moment, the procedure of listing revision underwent various changes. The last revisions of this legal document contained several amendments regarding orphan medications. So, in last version the rating scale included separate component related to these medications. This indicates at unique characteristics of orphan medications that not allow to consider them along with other medications. The article covers main stages of drug list forming procedures of making out restrictive listings of medications in the light of how available methodology is adapted to be applied to orphan medications.

Inflammatory Bowel Disease Patients’ Preferences for Subcutaneous versus Intravenous Therapies: A Mixed-Methods Study

Background: Multiple biologics are available to treat inflammatory bowel disease (IBD), which can either be administered subcutaneously or intravenously. The factors that determine patients’ preferences for SC/IV administration in IBD are largely unknown. This study aims to elucidate how IBD patients trade off between medications’ route of administration and other medication characteristics and to understand what drives patients’ preferences. Methods: We employed a mixed methods design using data from a prior quantitative conjoint analysis survey and a series of 22 qualitative interviews. We quantitatively assessed individual patients’ preferences for subcutaneous (SC) or intravenous (IV) medications based on the part-worth utilities derived from the conjoint analysis and identified predictors for these preferences. We used a qualitative analysis to identify key themes surrounding patients’ preferences in the interview data. Results: Of 1,077 survey participants, 49% preferred an SC medication every 2 weeks, whereas 51% preferred an IV medication every 8 weeks. More people preferred SC at reduced administration frequencies, whereas less people preferred SC at the expense of lower efficacy or higher side-effects rates. Prior experience with SC/IV was the strongest predictor for patients’ preferences. Qualitatively, we obtained in-depth insights in the perceived advantages and disadvantages of SC and IV medications and in patients’ preconceived ideas. Conclusion: While prior SC/IV exposure was a strong predictor for SC/IV preferences, patients’ preferences largely are determined by a variety of other personal factors. The themes we identified could help guide clinicians when discussing therapeutic options with their patients and support shared decision-making.

The Impact of Temperament and Character on Treatment Compliance of Opioid Agonists

Background: Opioid agonist treatment, as the most effective treatment for opioid dependency, requires patient adherence for its effectiveness over the long run. Previous studies on psychiatric and non- psychiatric patients indicated that the patient`s temperament has had effect on their treatment compliance. Some studies on different types of addiction have attributed special temperament and character traits to these patients. Introduction: This study aims to investigate the impact of temperament and characteristics on opioid treatment compliance. In this study, the relationship between demographic variables, type of medication therapy, and temperament and characteristics scales of patients against opioid agonists therapy compliance was examined Methods: In this cross-sectional study, 150 patients who had initiated the course of opioid agonist maintenance therapy underwent TCI 125-item test and were followed-up for 2 months regarding compliance. The data were inputted into SPSS 24. K-S and Mann-Whitney U tests were employed to explore the relationship between quantitative and qualitative variables, while for examining the relationship between qualitative variables with each other, Chi-square test was utilized. The significance level in the tests was considered p<0.05. Result: The treatment compliance in this study was 67.2%. In patients who did not have treatment compliance, scores of novelty-seeking (16.7±7versus11.7±4, p<0.001), harm avoidance (16.5±5versus 11.8±5, p<0.0001), reward dependence (12.4±3 versus 10.2±3, p=0.005) and self-transcendence (10.6±2 versus 8.7±2 p=0.002) were higher, but in those who had suitable treatment compliance, scores of persistence (3.5±1 versus 2.3±1, p=0.004) and cooperativeness (17.6±3 versus14.8±4, p=0.004) were higher. Further, some temperament traits were different among patients undergoing treatment with buprenorphine versus methadone (scores of persistence, self-directedness and self-transcendence were higher in the group receiving buprenorphine, while scores of harm avoidance and cooperativeness were higher in the group under methadone treatment). There was also a significant relationship between gender (good compliance: female 100%, male 65%, poor compliance female 0%, male 35%; p=0.04), level of education (higher), as well as type of medication (buprenorphine) and treatment compliance. Conclusion: The results of this study can help to identify high-risk individuals for withdrawing opioid addiction. These people can be a target for pharmacological and non-pharmacological interventions to have their personality traits modified. Investigation of the effect of performing these interventions on treatment compliance can be a subject of future study in this area. Also while there are differences in personality characteristics among cultures, this study investigated Iranian culture more precisely.

Factors which influence the deprescribing decisions of community-living older adults and GPs in Australia.

Deprescribing aims to reduce polypharmacy and inappropriate medication use. Both General Practitioners (GPs) and older adults have expressed a willingness to consider deprescribing. However, deprescribing is often deferred in practice. The aim of this study was to identify factors which influence GP and older adult decisions about deprescribing in primary care. Semi-structured interviews were used in this qualitative study, conducted in a regional area in Australia. Participants included GPs and adults aged 65 years or older, using five or more medications and living independently in the community. Data were collected between January 2018 and May 2019. Thematic analysis was used to analyse the verbatim transcribed interviews using NVivo 12. A total of 41 interviews were conducted, 25 with older adults and 16 with GPs. Four key themes influenced deprescribing decisions: views of ageing, shared decision-making, attitudes toward medication use and characteristics of the health care environment. Discussions of deprescribing were limited by the influence of negative stereotypes toward age and ageing, a lack of older adult participation in shared decision-making, a positive attitude towards ongoing medication use and perception of the normality of using medications in older age. Time constraints, poor communication about prescribing information and unclear roles regarding responsibility for deprescribing also prevented discussions. Continuity of care, involvement of older adults in medication reviews and GPs who asserted their generalist role were the main factors which promoted discussion of deprescribing. GPs are well placed to discuss deprescribing with their older patients because they are trusted and can provide continuity of care. Actively encouraging and involving older adults in medication reviews in order to understand their preferences, supports shared decision-making about deprescribing. Active involvement may also reduce the influence of negative views of ageing held by both older adults and GPs.

Adverse events during intra-hospital transport of critically ill patients: an observational study

Aim: This study aimed to describe adverse events occurring during intra-hospital transportation of adult patients from the emergency room to the intensive care unit and to analyze the associated risk factors. Design: This study uses a quantitative analytical observational design. Methods: In total, 151 critically ill patients out of 159 with indicated intra-hospital transportation participated in the study. Patients were transported from the emergency room to the intensive care unit in a class A general hospital in Central Java, Indonesia. The statistical analysis included descriptions of demographic, medication, monitoring, equipment, and clinical characteristics of the cohort, and identified risk factors for adverse events during transportation by univariate and multivariate logistic regression analyses. Results: The overall incidence of adverse events was 78.8%. Risk factors were: transport team, hemodynamic monitoring, equipment preparation, and patient’s condition, and were associated with adverse events (p < 0.05). Multivariate analysis showed that equipment preparation was the factor most contributing to adverse events with Exp(B) = 22.6. Conclusion: This study showed that the incidence of adverse events during transportation of critically ill patients was high. We recommend that transports be performed by fully equipped teams of medical professionals. Monitoring of intra-hospital transportation-related events is also recommended to reduce frequency of adverse events.

Development and validation of the INappropriate solid oral dosaGE form modification aSsessmenT (INGEST) Algorithm using data of patients with medication dysphagia from a neurology ward and nursing home in Singapore

ObjectivesThis study aims to develop and validate a novel implicit tool to assist clinicians in resource-limited settings to promptly assess suitability for modification of solid oral dosage forms (SODFs) during...

Mental Health-related Utilization of Emergency Departments During Pregnancy in the U.S., 2016-2019.

Mental health conditions are a leading comorbidity of pregnancy, but little is known about the use of emergency departments (EDs) for mental health-related care during pregnancy. This study aims to describe both the characteristics of pregnant women who receive mental health-related care in hospital EDs in the United States and the most common mental health diagnoses, types of medications, and mental health services that these women receive. Pooled, cross-sectional data from the National Hospital Ambulatory Medical Care Survey (2016-2019) were used. Pregnant patients were identified based on diagnosis and reason for visit codes. Weighted descriptive analyses were performed to describe characteristics of pregnant women, services offered, and medications received for mental health-related visits. Mental health-related visits comprised 6.2% of all ED visits during pregnancy. History of depression was significantly higher in pregnant patients with mental health-related visits compared to those pregnant patients presenting for other reasons. The most common diagnoses for pregnant patients with mental health-related visits were substance use disorders (30.7%), anxiety-related disorders (19.1%), and depressive disorders (14.6%). Anxiolytics and antidepressants were the most common pharmacotherapies given. Few women saw a mental health provider during their visit (6.7%), while most were referred to an outside clinic for follow-up (55.0%). Many pregnant women seek care from EDs for mental health-related reasons. It remains important to train health care professionals who treat pregnant women in EDs how to deliver effective treatments, particularly for substance use disorders and anxiety. Many pregnant patients receive care in emergency departments during pregnancy. Despite mental health conditions being a leading comorbidity of pregnancy, little is known about the use of emergency departments for mental health-related reasons during pregnancy. This study is the first to analyze a representative sample of emergency department visits by pregnant women in the United States between 2016 and 2019 and report on mental health-related visits. Among pregnant women seen in the ED for mental health-related reasons, the most common diagnoses were substance use disorders, anxiety-related disorders, and depressive disorders, but few saw a mental health provider during their visit.

Patient-Specific Factors Associated with Dexmedetomidine Dose Requirements in Critically Ill Children

AbstractThe objective of this study was to evaluate patient-specific factors associated with dexmedetomidine dose requirements during continuous infusion. A retrospective cross-sectional analysis of electronic health record-derived data spanning 10 years for patients admitted with a primary respiratory diagnosis at a quaternary children's hospital and who received a dexmedetomidine continuous infusion (n = 346 patients) was conducted. Penalized regression was used to select demographic, clinical, and medication characteristics associated with a median daily dexmedetomidine dose. Identified characteristics were included in multivariable linear regression models and sensitivity analyses. Critically ill children had a median hourly dexmedetomidine dose of 0.5 mcg/kg/h (range: 0.1–1.8), median daily dose of 6.7 mcg/kg/d (range: 0.9–38.4), and median infusion duration of 1.6 days (range: 0.25–5.0). Of 26 variables tested, 15 were selected in the final model with days of dexmedetomidine infusion (β: 1.9; 95% confidence interval [CI]: 1.6, 2.3), median daily morphine milligram equivalents dosing (mg/kg/d) (β: 0.3; 95% CI: 0.1, 0.5), median daily ketamine dosing (mg/kg/d) (β: 0.2; 95% CI: 0.1, 0.3), male sex (β: −1.1; 95% CI: −2.0, −0.2), and non-Black reported race (β: −1.2; 95% CI: −2.3, −0.08) significantly associated with median daily dexmedetomidine dose. Approximately 56% of dose variability was explained by the model. Readily obtainable information such as demographics, concomitant medications, and duration of infusion accounts for over half the variability in dexmedetomidine dosing. Identified factors, as well as additional environmental and genetic factors, warrant investigation in future studies to inform precision dosing strategies.

Hearing loss following the use of topical otitis therapeutics in dogs

Hearing loss occurring in temporal association with the topical application of otic medications is regularly reported to the Federal Office of Consumer Protection and Food Safety (Bundesamt für Verbraucherschutz und Lebensmittelsicherheit - BVL) in the form of adverse event (AE) reports. Although deafness or impaired hearing are listed as possible adverse reactions in the Summary of Product Characteristics of the otic medications approved in Germany little information about the underlying causes is available to date. A search for cases reporting impaired hearing following the use of otic medication was conducted in the national AE database. Subsequently, descriptive analysis was performed. Due to their small number, cases involving cats were excluded. Possible risk factors and causes of hearing loss were considered against the background of current literature. While dogs of all age groups were affected, the majority of reports referred to dogs older than 10 years of age. Besides crossbreds, dogs of the breeds West Highland White Terrier, Dalmatian, Miniature Poodle and French Bulldog were most frequently involved. The analysis of the available data does not point to specific products or active substances that could be associated with a more frequent occurrence of hearing loss. In addition to possible ototoxicity of a product, other causes of hearing loss should be considered. These include the underlying otitis itself, age-related hearing loss, previously undetected unilateral congenital deafness, or conductive deafness due to obstruction of the ear canal. Treatment options include discontinuation of potentially ototoxic substances or treatment of conductive deafness, e. g. by removal of drug residues and exudate or treatment of otitis media. In the case of hearing loss subsequent to the use of otic medication, the BVL should be notified of this event in as much detail as possible in order to further improve the data situation concerning this topic.

Gut microbiome changes in anti-N-methyl-D-aspartate receptor encephalitis patients

BackgroundAnti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a type of autoimmune encephalitis. The underlying mechanism(s) remain largely unknown. Recent evidence has indicated that the gut microbiome may be involved in neurological immune diseases via the "gut-brain axis". This study aimed to explore the possible relationship between anti-NMDAR encephalitis and the gut microbiome.MethodsFecal specimens were collected from 10 patients with anti-NMDAR encephalitis and 10 healthy volunteers. The microbiome analysis was based on Illumina sequencing of the V3-V4 hypervariable region of the 16S rRNA gene. The alpha, beta, and taxonomic diversity analyses were mainly based on the QIIME2 pipeline.ResultsThere were no statistical differences in epidemiology, medication, and clinical characteristics (except for those related to anti-NMDAR encephalitis) between the two groups. ASV analysis showed that Prevotella was significantly increased, while Bacteroides was reduced in the gut microbiota of the patients, compared with the controls. Alpha diversity results showed a decrease in diversity in the patients compared with the healthy controls, analyzed by the Shannon diversity, Simpson diversity, and Pielou_E uniformity based on the Kruskal–Wallis test (P = 0.0342, 0.0040, and 0.0002, respectively). Beta diversity analysis showed that the abundance and composition of the gut microbiota was significantly different between the two groups, analyzed by weighted and unweighted UniFrac distance (P = 0.005 and 0.001, respectively).ConclusionsThe abundance and evenness of bacterial distribution were significantly lower and jeopardized in patients with anti-NMDAR encephalitis than in healthy controls. Thus, our findings suggest that gut microbiome composition changes might be associated with the anti-NMDAR encephalitis. It could be a causal agent, or a consequence.

Morphine Equianalgesic Dose Chart in the Emergency Department.

Morphine Equianalgesic Dose Chart in the Emergency Department.

Midline Catheters: Could They Replace a Central Vascular Access Device?

In the past 30 years, midline catheter use has grown rapidly. For several reasons, many providers and facilities are attempting to reduce the number of central venous catheters and subsequent central line-associated bloodstream infections (CLABSIs) by using midline catheters. Vessel preservation requires attention to all vascular access device (VAD)-associated complications and not only central line bloodstream infection. There is still much confusion about the appropriate tip location and the characteristics of fluids and medications that can safely be infused through a midline catheter residing in a peripheral vein. The Infusion Therapy Standards of Practice (the Standards) focuses on assessment of characteristics of infusion therapies that must be considered for VAD selection as an evidence-based list of fluids and medications for infusion through peripheral veins has yet to be established. This review of midline catheter studies evaluates the evidence regarding the substitution of a midline catheter for a central venous catheter. Many issues need to be addressed, such as studies that include an outcome list that mixes defined clinical complications (eg, thrombosis) with signs and symptoms of complications (eg, leaking). Another issue is basing a major change of clinical practice on retrospective chart reviews. Although a midline catheter may be appropriate for some patients, additional studies of a higher level of evidence are needed before this major practice change should occur.

Abstracts 8th PCNE working symposium ‘Navigating research on pharmaceutical care’. 11–12 February 2022, Lisbon, Portugal

Abstracts 8th PCNE working symposium ‘Navigating research on pharmaceutical care’. 11–12 February 2022, Lisbon, Portugal